Sunday, July 28, 2013

UCB Announces New Results From Phase 2b Open-Label Extension Study Evaluating The Long-Term Effects Of Epratuzumab In SLE

UCB have announced new data from an open-label extension (SL0008) of the EMBLEM™ phase 2b study evaluating the long-term effects of epratuzumab treatment in adult patients with moderate-to-severe systemic lupus erythematosus (SLE). more...

1 comment:

  1. That is great news.

    how 'bout putting order status of orders on site?
    I know you are backlogged, but an idea of approximately when they will ship would be good.
    "Weeks" is really not a very good clue.

    ReplyDelete